A standing platform for testing new drugs with radiotherapy
Radiotherapy is given to half of all cancer patients but few new drugs are tested alongside it. A permanent trial platform would test drug-plus-radiation pairs systematically.
Radiosensitisers and immune-radiation combinations have strong biological rationale but almost no industry sponsorship because radiotherapy is unpatentable. The CONCORDE platform in the UK tests DNA-damage-response inhibitors with thoracic radiotherapy. Extending the model to a standing multi-tumour radiotherapy-drug platform with dose-finding modules and a shared radiotherapy quality-assurance backbone would fill a systematic gap.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Surgery and radiotherapy cure most, get least · Surgery and radiotherapy cure more people than drugs do, but attract a fraction of the research investment.
Pages like this
not linked directly; found by shared links- TechnologyBoron neutron capture therapy
Shares Glioma & glioblastoma, Head and neck squamous cell carcinoma.
- PersonDeborah Watkins Bruner
- IdeaFactorial trials that test several cheap generics at once in the adjuvant setting
- IdeaA perpetual platform trial in every major cancer, funded as infrastructure
Shares Too many combinations to test, Cancer Research UK, Glioma & glioblastoma.
- PersonVanita Noronha
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- IdeaA standing platform trial for every major cancer, funded as infrastructure
Shares Too many combinations to test, Glioma & glioblastoma.
- IdeaTwo-week pre-operative windows to compare combination biology head to head
Shares Too many combinations to test, Head and neck squamous cell carcinoma.
- PersonHye Ryun Kim
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer.